🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementHair falling out at month 4 - freaking out — looking for input

Hair falling out at month 4 - freaking out — looking for input

marcus_mpls Tue, Sep 24, 2024 at 2:43 AM 19 replies 2,179 viewsPage 1 of 4
This thread is more than 20 months old. Information may be outdated. Consider searching for more recent discussions.
marcus_mpls
Member
234
1,123
Nov 2024
Minneapolis, MN
Sep 24, 2024 at 2:43 AM#1

Nausea arrived on day two of each dose step, lasted about four days, and disappeared entirely by the second week — until the step where it did not.

The narrow version of the question is whether holding at a lower dose for longer actually reduces total side-effect burden or just spreads it out.

Not looking for reassurance. Looking for the part I have got wrong.

3 23bbq_ray_KC, oliver_london, tane_welly
Reply Quote Save Share Report
TrialNerd_Beth
Senior Member
2,345
11,234
Jan 2024
Bethesda, MD
Sep 24, 2024 at 3:21 AM#2

Answering the narrow version, because the broad one does not have a single answer. Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts. Receptor-level tachyphylaxis to the delayed-emptying effect develops over weeks while the central appetite effect persists, so the same dose is materially more comfortable at week six than at week two. A slower ladder therefore reaches the same dose with less cumulative nausea, not the same nausea spread thinner.

2 22PharmHunterJen, TomTeleRx
Reply Quote Save Share Report
greg_boulder
Member
345
1,567
Jul 2024
Boulder, CO
Sep 24, 2024 at 3:59 AM#3
TrialNerd_Beth said:
Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts.

Agreed on adaptation, with a caveat: adaptation applies to gastric emptying and not to everything. If your problem is the aversion rather than the fullness, waiting does less, because the aversion is central and it is the mechanism working as intended.

Last edited: Sep 24, 2024 at 5:59 AM
1 21Dr.DermMIA
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
pat_auckland
Member
345
1,567
Jun 2024
Auckland, NZ
Sep 24, 2024 at 4:37 AM#4
marcus_mpls said:
Nausea arrived on day two of each dose step, lasted about four days, and disappeared entirely by the second week — until the step where it did not.

Same position here, arrived at the long way round. The line between titrate-through and stop is not severity, it is trajectory and what else is present. Nausea that peaks and improves within a week is the expected pattern. Nausea that is escalating, or that comes with severe upper-abdominal pain radiating to the back, or that prevents fluids for more than a day, is a different conversation and belongs with a clinician the same day.

Last edited: Sep 24, 2024 at 8:37 AM
50 20MeganSA_TX, LarryQC_SD, wanda_boise and 47 others
Reply Quote Save Share Report
paige_pharma
Member
289
1,234
Sep 2024
Omaha, NE
Sep 24, 2024 at 8:11 AM#5

From the other side of the consultation, briefly. Take it one variable at a time. Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent argument can untangle them after the fact.

49 19lucas_SP_BR, lisa_labSD, adam_van and 46 others
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register